McKesson to spin off Medical-Surgical Solutions segment, focus on high-growth oncology and biopharma markets 

IRVING, Texas – McKesson Corp. has announced plans to separate its Medical-Surgical Solutions segment into an independent company.

This strategic move is aimed at sharpening McKesson’s focus on higher-growth, higher-margin opportunities in Oncology and Biopharma Solutions, aligning with its long-term enterprise strategy. 

“Disciplined capital deployment and portfolio management are hallmarks of our strategy,” said Brian Tyler, CEO of McKesson. “This separation is designed to unlock significant value for both McKesson and Medical-Surgical Solutions, enabling each to pursue growth and operational excellence in their respective markets.” 

Strategic realignment and growth focus 

The planned spin-off reflects McKesson’s commitment to portfolio optimization and capital efficiency, allowing the company to intensify investments in sectors with strong growth potential. The new standalone medical-surgical supply and solutions company is expected to benefit from: 

• A strong leadership position in alternate sites of care 
• Attractive profit margins 
• Accelerated growth potential across diversified health care markets 

Oncology expansion through CORE Ventures acquisition 

In a parallel move to strengthen its oncology footprint, McKesson recently acquired a 70% controlling interest in CORE Ventures for $2.49 billion. CORE Ventures, founded by Florida Cancer Specialists & Research Institute (FCS), supports more than 250 physicians and 280 advanced practice providers across nearly 100 locations in Florida. This acquisition enhances McKesson’s capabilities in community oncology services and administrative support solutions. 

What’s next? 

McKesson is currently evaluating the form and timing of the separation and is committed to executing the transaction in a way that maximizes shareholder value. Additional details will be shared as the process advances.